Optimizing efficiency in relapsed or refractory multiple myeloma treatment in Greek National Health System hospitals: estimating the impact of using subcutaneous versus intravenous daratumumab

RESEARCH ARTICLE

Hippokratia 2024, 28(4): 158-164

Golnas P, Golna C, Kontogiorgos Y, Christodoulou T, Konstantopoulou T, Souliotis K
Health Policy Institute, Maroussi, Janssen Hellas, Pefki, Department of Social and Education Policy, University of Peloponnese, Corinth, Greece